GSK plans $100M makeover of US manufacturing site; La Jolla Pharma gets a ‘breakthrough’ with late-stage drug

SourceEndpoints News (
Date Published04/24/2019
Author NameKathy Wong
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name GlaxoSmithKline
Parent companyGlaxoSmithKline
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2019
Capital investment ($):100
Country(ies) from which reshored:United Kingdom
City reshored to:Hamilton
State(s) reshored to:MT
If relevant, work nearshored to:-
Product(s) reshoredvaccine adjuvants
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Proximity to customers/market, Other, expansion of current production
Find Reshoring Articles